




Meta and bioinformatics analysis of SNP of proteasome genes as possible molecular markers for multiple sclerosis case/control study in Latvian population

I. Trapina, Dr.med.


Genomica and Bioinformatic Institute of Biology, University of Latvia

Daugavpils, 2019

Multiple sclerosis








Multiple sclerosis (MS) involves an immune-mediated process in which an abnormal response of the body's immune system is directed against the central nervous system (CNS: brain, spinal cord and optic nerves). Therfore MS is **autoimmune inflammatory disease**.

Within the CNS, the immune system causes **inflammation that damages myelin** — the fatty substance that surrounds and insulates the nerve fibers — as well as the nerve fibers themselves, and the specialized cells that make myelin. When myelin or nerve fibers are damaged or destroyed in MS, **messages** within the CNS are **altered** or **stopped** completely.

Damage to areas of the CNS may produce a variety of **neurological symptoms** that will vary among people with MS in **four** disease courses (**types**) and severity.

The cause of MS is not known, but it is believed to **involve genetic susceptibility**, abnormalities in the immune system and environmental factors that combine to trigger the disease.




SPMS


PPMS

RRMS

Possible links between proteasome and multiple sclerosis


Proteasomal system: Proteasomes, the multycatalytic protease complexes, play a critical role in the degradation of proteins via ATP/ubiquitin-dependent process or ubiquitin proteasome system, which plays a crucial role in immunity and its disregulation and/or modulation may influence the development and progression of different diseases.





20S proteasome induction with **interferon** causes replacement of PSMB5, PSMB6 and PSMB1 by LMP2 (PSMB8), LMP7 (PSMB9) and MECL-1 (PSMB10) (multicatalytic endopeptidase complex subunit), respectively, and forms **immunoproteasome**. Expression of LMP2 and LMP7 genes is decreased in patients with autoimmune diseases.

The proteolytic **activities of proteasomes** are **reduced** in brain tissue of <u>Multiple sclerosis</u> <u>patients</u>. The **20S proteasome** had been identified **as a target** of the humoral autoreactive **immune response** and a major autoantigen in MS patients.



Jansen et.al, Front. Mol. Neurosci., 2014

Aim of the study


To determine the prevalence and possible **functionality SNPs** of **proteasome** gene to analyze their usability as **molecular markers** for **multiple sclerosis binding study** in the Latvian population.

Materials and methods

Six SNPs of proteasomal genes:

1.PSMB8 (LMP7) - proteasome subunit beta 8:

- I. rs2071543 > NM_004159.4:c.135+427C>A (Gln49Lys)
- II. rs9357155 > NM_148919.3:c.537+63C>T (G>A)
- III. rs9275596 > NT_167246.1:g.4138777T>C
- 2. PSMB9 (LMP2) proteasome subunit beta 9
 - I. rs17587 > NM_002800.4:c.179G>A
- 3. PSMD9 proteasome 26S subunit, non-ATPase 9
 - I. rs74421874 > NM_002813.6:c.454-460G>A
 - II. rs3825172 > NM_002813.6:c.454-437C>T





✓ Meta analyze of scientific literature

- ✓ Bioinformatical tools:
 - Transcription factor binding site > MatInspector

(http://www.genomatix.de) with identity 1,00 of core and >0,85 of matrix

DNA bendabilty > bent.it (Vlahovicek et al., 2003;

http://pongor.itk.ppke.hu/dna/bend_it.html#/bendit_form)


> **DNA and/or RNA secondary structure > Mfold** (Zuker 2003,

http://unafold.rna.albany.edu/?q=mfold/DNA-Folding-Form)


PSMB8 - rs2071543: NM_004159.4:c.135+427C>A (Gln49Lys)


MAF in EUR: 0.15

Transcription factor binding site




RNA secondary structure






DNA bendabilty (green line) in areal **decreases** at change of nucleotide C>A




Sequence



PSMB8 - rs9357155: NM_148919.3:c.537+63C>T (G>A)

MAF in EUR: 0.31

20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Matrix similarity



Transcription factor binding site

DNA secondary structure

Second and some G A G rs9357155-A rs9357155-G A Predicted curvature Predicted curvature Rendabilit Rendahilit s/10.5 bp 5.4 5.2 1.5 4.8 4.6 4.4 4.2 40 45 50 55 60 65 65

Sequence


Sequence

DNA bendabilty (green line) in areal increases at change of nucleotide G>A

PSMB8 - rs9275596 > NT_167246.1:g.4138777T>C


MAF in EUR: 0.14


Transcription factor binding site



DNA secondary structure

DNA bendabilty (green line) in areal increases at change of nucleotide T>C






PSMB9 - rs17587 > NM_002800.4:c.179G>A MAF in EUR: 0.27


G







DNA secondary structure

DNA bendabilty (green line) in areal **no difference** at change of nucleotide G>A








PSMD9 - rs74421874: NM_002813.6:c.454-460G>A and rs3825172: NM_002813.6:c.454-437C>T


in complete **linkage disequilibrium** with <u>MAF in EUR: 0.31</u> for both SNPs (between are 23 bp)


Transcription factor binding site




PSMD9 - rs74421874: NM_002813.6:c.454-460G>A and rs3825172: NM_002813.6:c.454-437C>T


DNA secondary structure





DNA bendabilty (green line) in areal increases at change of nucleotide G/C>A/T





Conclusions

Meta and bioinformatic analysis of selected SNPs of PSMB8 (rs2071543, rs9357155 and rs9275596), PSMB9 (rs17587) and PSMD9 (rs74421874 and rs3825172) illustrate possibility of using them as molecular markers of multiple sclerosis by genotyping in association study.



Thank you for your attention!



SAM No 1.1.1.1/16/A/016 project "Determination of proteasomerelated genetic, epigenetic and clinical markers for multiple sclerosis"